R&D Centers

R&D Center in China

Key R&D Capabilities

Long-acting and Extended Release Technology

Liposome and Targeted Drug Delivery Technology

Biological Antibody Technology

NME Platforms

Innovative Medical Technology

R&D Center in the U.S.

Key R&D Capabilities

International R&D Collaboration

Exploratory Study for Innovative Drugs

Innovative Medical Technology

 

R&D Center in Europe

Key R&D Capabilities

Transdermal Drug Delivery Technology

Granted Patents

246 patents granted in China

and another 78 applications in progress.

606 patents granted overseas

while 129 applications in progress.

(As of July 2022)

Platforms and Technologies

Novel Drug Delivery Systems (NDDS)& New Molecular Entity(NME)Platforms

Novel Drug Delivery Systems(NDDS):

Long-acting and extended release technology,

Liposome and targeted drug delivery technology,

Transdermal drug delivery technology;

Novel Drug Delivery Systems (NDDS)& New Molecular Entity(NME)Platforms

New Molecular Entity (NME) Platforms:

NCE platform (new chemical entity based on innovative targets and PROTACs); NTE platform (new therapeutic entity based on improving physicochemical properties); PDC platform (peptide drug conjugate); key technical processes such as target discovery, drug design and synthesis, screening and evaluation have been established, with more than 10 projects launched to find new drug candidates;

Antibodies

Human Antibody Transgenic Mouse and Phage Display Technology Platform:

BA-huMab® platform: Directly generate human antibodies without need for humanization, which significantly accelerates antibody discovery process and decreases immunogenicity risk; Elicit an immune response quickly and produce a high antibody titer after immunization; Phage display technology platform: Efficient animal immunity technology; Mature phage library construction technology; High-throughput and diverse phage based panning strategies; Diverse evaluation capabilities for antibodies or antibody fragments;

Antibodies

Bispecific T-cell Engager Technology Platform:

Demonstrate high avidity with tumor target antigen by bivalent binding to achieve better drug efficacy; Demonstrate low affinity with T cells by monovalent binding to lower toxicity; Reduce CD3 antibody binding affinity, to significantly reduce the risk of CRS;

Antibodies

ADC Technology Platform:

Design, synthesize and screen the potential ADC linker-payload; Identification of potential internalized antibodies; Diverse antibody conjugation technologies; Evaluation of ADC in vitro and in vivo; Process development and quality analysis for ADC products;

Innovative Therapies

Nucleic Acid Therapy and Gene Therapy:

Research and development of novel therapies including AAV-based gene therapy and nucleic acid therapy (mRNA and Oligo). Both harbor significant potential to address a wide spectrum of diseases;

Innovative Therapies

Gene and Nucleic Acid Targeted Delivery:

Delivery is a critical enabling element in nucleic and gene therapy. The proprietary LNP platform adds value to the pipeline by enabling tissue and organ specific delivery;

Innovative Therapies

CAR-T Cell Immunotherapy:

Developing next-generation cell therapy technologies engineered to target neo-tumor antigens and accomplish other therapeutic functions. Novel non viral vector technology to enhance manufacturing efficiency. Improve cancer treatment by providing a personalized therapy option;

R&D Pipelines

Key Laboratory

The Laboratory of Long-acting and Targeting Drug Delivery System, focusing on the research of:

Long-acting drug delivery system and drug release technology

Targeting drug delivery system and drug release technology

High-end carrier materials for long-acting and targeting drug delivery

R&D Centers

located in China, the United States
and Europe

Robust R&D pipelines of drug candidates:

30+ in China

10+ overseas


800+ R&D professionals

R&D Centers

R&D Center in the U.S.

Key R&D Capabilities

Exploratory Study for Innovative Drugs

International R&D Collaboration

Innovative Medical Technology

R&D Center in China

Key R&D Capabilities

Long-acting and Extended Release Technology

Liposome and Targeted Drug Delivery Technology

Biological Antibody Technology

NME Platforms

Innovative Medical Technology

R&D Center in Europe

Key R&D Capabilities

Transdermal Drug Delivery Technology

Granted Patents

246 patents granted in China

and another 78 applications in progress.

606 patents granted overseas

while 129 applications in progress.

(As of July 2022)

Platforms and Technologies

Novel Drug Delivery Systems (NDDS)& New Molecular Entity(NME)Platforms

Novel Drug Delivery Systems(NDDS):

Long-acting and extended release technology,

Liposome and targeted drug delivery technology,

Transdermal drug delivery technology;

Novel Drug Delivery Systems (NDDS)& New Molecular Entity(NME)Platforms

New Molecular Entity (NME) Platforms:

NCE platform (new chemical entity based on innovative targets and PROTACs); NTE platform (new therapeutic entity based on improving physicochemical properties); PDC platform (peptide drug conjugate); key technical processes such as target discovery, drug design and synthesis, screening and evaluation have been established, with more than 10 projects launched to find new drug candidates;

Antibodies

Human Antibody Transgenic Mouse and Phage Display Technology Platform:

BA-huMab® platform: Directly generate human antibodies without need for humanization, which significantly accelerates antibody discovery process and decreases immunogenicity risk; Elicit an immune response quickly and produce a high antibody titer after immunization; Phage display technology platform: Efficient animal immunity technology; Mature phage library construction technology; High-throughput and diverse phage based panning strategies; Diverse evaluation capabilities for antibodies or antibody fragments;

Antibodies

Bispecific T-cell Engager Technology Platform:

Demonstrate high avidity with tumor target antigen by bivalent binding to achieve better drug efficacy; Demonstrate low affinity with T cells by monovalent binding to lower toxicity; Reduce CD3 antibody binding affinity, to significantly reduce the risk of CRS;

Antibodies

ADC Technology Platform:

Design, synthesize and screen the potential ADC linker-payload; Identification of potential internalized antibodies; Diverse antibody conjugation technologies; Evaluation of ADC in vitro and in vivo; Process development and quality analysis for ADC products;

Innovative Therapies

Nucleic Acid Therapy and Gene Therapy:

Research and development of novel therapies including AAV-based gene therapy and nucleic acid therapy (mRNA and Oligo). Both harbor significant potential to address a wide spectrum of diseases;

Innovative Therapies

Gene and Nucleic Acid Targeted Delivery:

Delivery is a critical enabling element in nucleic and gene therapy. The proprietary LNP platform adds value to the pipeline by enabling tissue and organ specific delivery;

Innovative Therapies

CAR-T Cell Immunotherapy:

Developing next-generation cell therapy technologies engineered to target neo-tumor antigens and accomplish other therapeutic functions. Novel non viral vector technology to enhance manufacturing efficiency. Improve cancer treatment by providing a personalized therapy option;

R&D Pipelines

Overseas R&D Pipelines
R&D Pipelines in China

Key Laboratory

The Laboratory of Long-acting and Targeting Drug Delivery System, focusing on the research of:

Long-acting drug delivery system and drug release technology

Targeting drug delivery system and drug release technology

High-end carrier materials for long-acting and targeting drug delivery